Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Toni Choueiri, MD Profile picture
Toni Choueiri, MD
@DrChoueiri
Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; ⚽ lover; 🚲@PanMass rider.
Jan 1 • 11 tweets • 7 min read
END OF YEAR TOP ALL CANCER TRIALS in 2024!

JUST in on 1 JAN 2025:

Paper 1:

#neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO @ProfCUBlankNKI

nejm.org/doi/full/10.10…Image
Image Paper 2:

The #TRANSMET study shows liver transplantation + chemo improves 5-year survival (56.6%) vs chemo alone (12.6%) for unresectable colorectal liver metastases. A potential game-changer in colorectal liver metastases! @TheLancetOncol



@GelliMaximilia1 @CHBPaulBrousse @GustaveRoussythelancet.com/journals/lance…Image
Dec 27, 2024 • 10 tweets • 8 min read
IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024

1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos
⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45)
⏩ OS benefit: 31.5 vs 16.1 mo (HR= 0.47)

@tompowles1 @NEJM #ESMO2023 Plenary

nejm.org/doi/full/10.10…Image
Image 2/NIAGARA trial: Perioperative durvalumab with NAC in operable bladder cancer à EFS and OS benefit.
⏩32% reduction in risk of recurrence/death
⏩ 25% reduction in the risk of death
⏩No new safety signals.
🎯Potential new SOC for cisplatin-eligible MIBC!

#ESMO2024 Plenary

@tompowles1 again @NEJM

nejm.org/doi/full/10.10…Image
Image
Dec 26, 2023 • 11 tweets • 7 min read
And now, onto the Top 10 Translational GU Papers of 20-23. Again, not an exhaustive list, with some our @DanaFarber @DanaFarber_GU being involved in.

Let us start! Image 1/#RCC histological subtypes display diverse epigenetic configurations. Allelic imbalances play a role in modifying TF binding sites, especially through candidate SNPs.

Potential targets for future investigations and therapeutic strategies?

@AminNassarMD @sarahaboualaiwi @SylvanBacaLab #FreedmanLab

nature.com/articles/s4146…Image
Image
Image
Dec 24, 2023 • 11 tweets • 9 min read
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag

This is not an exhaustive list!

@OncoAlert @danafarber @DanaFarber_GU

#OnwardFor2024 Image 1/#COSMIC-313 phase 3 trial shows ⬆️PFS with Cabozantinib plus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic #RCC presented @myESMO #ESMO22

@motzermd @NEJM @tompowles1 @AlbigesL @DrDanielHeng @FabioSchutz78 @BurottoMauricio



COI: trial PInejm.org/doi/full/10.10…Image
Dec 29, 2022 • 11 tweets • 21 min read
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022:

Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag anyone involved

This is not an exhaustive list!

@OncoAlert @DanaFarber

#OnwardFor2023 Image 1/ #ARASENS phase 3 trial shows ⬆️OS with darolutamide in combination with docetaxel and ADT in #mHSPC (vs docetaxel + ADT alone) with similar AE profile, leading to @US_FDA approval.
#MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM
nejm.org/doi/full/10.10… ImageImageImage
May 27, 2022 • 10 tweets • 7 min read
Now that #ASCO22 abstracts are released, more insights into Top 10 #GUOnc abstracts (still many LBAs):

@DanaFarber_GU @OncoAlert @ASCO @ASCOPost

1/LBA| Chris Ryan @OHSUKnight=>The long awaited EVEREST study with adjuvant everolimus in RCC: stay tuned! 2/Interesting relationship between DepOR and clinical outcomes in CM-9ER! Greater proportions of pts receiving Nivo+Cabo had deeper responses vs SUN. This translated into better PFS/OS

Dr. Cristina Súarez @vallhebron Image
Dec 28, 2021 • 22 tweets • 42 min read
It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021:

Some negative, some positive, some led to @FDAOncology approval; we learned from all!

Feel free to add & retweet & tag anyone involved

This is not an exhaustive list

@OncoAlert 1/ (177Lu)–PSMA-617 showing improved PFS and OS in pre-treated mCRPC patients vs. SOC, in addition to a favorable safety profile @sartor_oliver @morr316 @NEJM
nejm.org/doi/full/10.10…
Aug 18, 2021 • 16 tweets • 8 min read
1/ On the heels of @ASCO #ASCO21 plenary, we are happy to share the results of KEYNOTE-564 trial of adjuvant pembrolizumab in mRCC just published in @NEJM ! A step towards better outcomes for all our patients with kidney cancer!
nejm.org/doi/full/10.10…
@OncoAlert @tompowles1 2/ Following nephrectomy for kidney cancer, a significant percentage of patients will experience disease recurrence, most of them with distant metastases, highlighting the need for effective adjuvant therapies.
Apr 22, 2021 • 16 tweets • 12 min read
Just out @NatureMedicine: Inhibition of HIF-2 alpha in RCC with belzutfian (MK-6482) - phase 1 trial and biomarker analysis- 1st study to report on the 2nd gen. HIF-2 inhibitors in pts with metastatic ccRCC!! @OncoAlert

A THREAD!

nature.com/articles/s4159… 1/The HIF2 axis biology is fascinating culminating in a 2019 @nobel prize, including our own @DanaFarber @kaelin_lab
Jun 22, 2020 • 13 tweets • 11 min read
Proud of this @NatureMedicine collaboration with #FeedmanLab on a novel method detecting early stage RCC in plasma&urine w/cell-free DNA methylomes. Work led by super stars @PierVitaleNuzzo @Jberchuck @keegankorthauer #SandorSpisak 1/ RCC kills 175,000 patients worldwide with no screening test available acsjournals.onlinelibrary.wiley.com/doi/full/10.33….
A screening test that detects RCC while still localized (2/3 RCCs) will possibly reduce mortality. RCC and CNS tumors do not shed much cfDNA in the blood!
May 29, 2020 • 19 tweets • 14 min read
1/ Our latest work was just published in @NatureMedicine!
Congratulations to first author Super-Star @BraunMDPhD and to all authors. #CathyWu #SachetShukla @LabSignoretti @VanAllenLab #FreemanLab #SharpeLab
@DanaFarberNews @DanaFarber
#kcsm #KidneyCancer
doi.org/10.1038/s41591… 2/ Our study analyzes patient samples from 3 prospective clinical trials of PD-1 blockade.
The study includes 592 tumors that were profiled by WES, RNA-seq, and/or IF for CD8+ T cells on samples collected before treatment with Nivolumab (anti-PD1) or Everolimus (mTOR inhibitor)